Alzheimer’s Disease Treatment: Canadian-Led Innovation Post-Aducanumab
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading…